The Promomed Group is introducing the first innovative drug of its kind to the Russian market for the treatment of community-acquired pneumonia. The product was presented at the BioPharm forum in Gelendzhik.
The active substance of Ambervin Pulmo is a synthetic peptide composed of six amino acids, linked to a fragment of succinic acid, GxP News found out from the group’s press service.
“At the core of Ambervin Pulmo, we have combined a peptide, which is an analogue of a natural bioregulator, with a fragment of succinic acid. This provides unique properties: firstly, anti-inflammatory and reparative effects, meaning tissue restoration. Secondly, the drug acts as an antioxidant and detoxifier: it helps eliminate harmful substances and reduces their negative impact,” explained Kira Zaslavskaya, Director of New Products at Promomed. According to her, the efficacy of the new drug has been proven for treating respiratory infections. In the future, it will also be used for cardiovascular diseases, as well as for wound and burn treatment.
The drug is manufactured at the biopharmaceutical plant of AO Biokhimik. Ambervin Pulmo is available in the form of injections and inhalation solutions, allowing for use at home: the medication will be available in pharmacies starting from the second half of October. Currently, the drug is being supplied through the government procurement segment for hospitals.
“The introduction of this drug into clinical practice will allow the healthcare system to meet all existing needs for comprehensive therapy of infectious diseases and prevention of life-threatening conditions at any time,” the press service emphasized.
Ambervin Pulmo is included in the Ministry of Health’s methodological guidelines for the prevention, diagnosis, and treatment of COVID-19, as well as in the list of Vital and Essential Drugs (VED).
